ASTRO 2022 | Rationale and study design of a Phase III study of sorafenib and SBRT for hepatocellular carcinoma

Laura A. Dawson, MD, FASTRO, Princess Margaret Cancer Center, Toronto, Canada, explains the need for an improved therapy for patients with unresectable hepatocellular carcinoma (HCC) that is unsuitable for ablation or regional therapy such as TACE. Treatment options for these patients was previously limited to systemic therapy, specifically sorafenib, which is insufficient. A randomized Phase III study by NRG Oncology (NCT01730937) is comparing stereotactic body radiation therapy (SBRT) plus sorafenib to sorafenib alone, with the hypothesis that SBRT plus sorafenib will improve patient outcomes. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.